TITLE

Association Between Proton Pump Inhibitor Use and Anemia: A Retrospective Cohort Study

AUTHOR(S)
Sarzynski, Erin; Puttarajappa, Chethan; Xie, Yan; Grover, Madhusudan; Laird-Fick, Heather
PUB. DATE
August 2011
SOURCE
Digestive Diseases & Sciences;Aug2011, Vol. 56 Issue 8, p2349
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Background: Proton pump inhibitors (PPIs) are widely prescribed to treat gastrointestinal diseases. However, concerns have been raised regarding their long-term use. Gastric acid suppression may decrease iron absorption, and it remains uncertain whether iron-deficiency anemia may result from chronic PPI therapy. Aims: We aimed to explore the association between chronic PPI use and iron-deficiency anemia. Methods: We conducted a retrospective cohort study of adult patients in an academic outpatient setting who received PPI therapy for at least 1 year between January 1, 2004 and January 1, 2006. We compared the change in hematologic indices among patients receiving PPI therapy for at least 1 year with matched controls. Results: Of the 98 patients on chronic PPI therapy who met inclusion criteria, 35% had no documented indication for such therapy. At baseline, demographics and hematologic indices were similar between PPI-users and controls. Among patients on PPI therapy, all hematologic indices decreased from baseline, including hemoglobin (−0.19 g/dL, P = 0.03), hematocrit (−0.63%, P = 0.02), and mean corpuscular volume (−0.49 fL, P = 0.05). PPI users had significant decreases in mean hemoglobin and hematocrit ( P < 0.01 for both) compared with matched controls. After adjustment for confounders, including rates of esophagogastroduodenoscopy, colonoscopy and remote cancer status, the odds ratio of decreasing hemoglobin by 1.0 g/dL while on chronic PPI therapy was 5.03 (95% CI, 1.71-14.78, P < 0.01), while the odds ratio of decreasing hematocrit by 3% was 5.46 (95% CI, 1.67-17.85, P < 0.01). Conclusions: Among adult patients receiving chronic PPI therapy, there is a significant decrease in hematologic indices from baseline.
ACCESSION #
63286541

 

Related Articles

  • Evolución epidemiológica de la enfermedad ácido péptica en un Centro de endoscopia diagnóstica de Bogotá entre 1993 y 2007. Arango, Luis Alberto Ángel; Boada, Diego Gómez; Díaz, María Paula Villalba // Revista Colombiana de Gastroenterología;Jun2010, Vol. 25 Issue 2, p139 

    Objective: To describe epidemiological characteristics of individuals suffering from acid peptic disease found by a first level endoscopic diagnostic center from 1993 and 2007. Methods: A retrospective, descriptive and analytical study of series of patients. Results: 12,638 registers were...

  • Rabeprazole: quest for the best PPI. Sugano, Kentaro // Journal of Gastroenterology;2002, Vol. 37 Issue 3, p233 

    Editorial. Comments on an article dealing with the effects of proton pump inhibitors (PPI) rabeprazole and omeprazole on parietal cells and other acid regulatory cells in the rat stomach. Details on the study; Background on PPI; Recommendations.

  • Cardiovascular and gastrointestinal events of three antiplatelet therapies: clopidogrel, clopidogrel plus proton-pump inhibitors, and aspirin plus proton-pump inhibitors in patients with previous gastrointestinal bleeding. Tsai, Yi-Wen; Wen, Yu-Wen; Huang, Weng-Foung; Chen, Pei-Fen; Kuo, Ken; Hsiao, Fei-Yuan // Journal of Gastroenterology;Jan2011, Vol. 46 Issue 1, p39 

    Background: Concomitant use of antiplatelet agents and proton-pump inhibitors (PPIs) has been recommended in patients with a history of gastrointestinal (GI) hemorrhage. However, recent studies have reported that PPIs may alter clopidogrel's pharmacokinetics and potentially lead to an increased...

  • GI Cancer Associated with Iron Deficiency Anemia. Shaughnessy, Allen // American Family Physician;3/15/2003, Vol. 67 Issue 6, p1339 

    Discusses the study 'Iron Deficiency and Gastrointestinal Malignancy: A Population-based Cohort Study,' by G. Ioannou et al., from the September 2002 issue of the 'American Journal of Medicine.'

  • Pantoprazole. Smith, Candace // Formulary;Jan2000, Vol. 35 Issue 1, p28 

    Pantoprazole is an irreversible proton pump inhibitor that effectively reduces gastric acid secretion. In clinical trials, pantoprazole has been well tolerated and efficacious in the treatment of both duodenal and gastric ulcers as well as gastroesophageal reflux disease. Preliminary results...

  • Newest proton pump inhibitor approved for gastrointestinal ills. Portyansky, Elena // Drug Topics;9/20/99, Vol. 143 Issue 18, p29 

    Presents information on the proton pump inhibitor (PPI) Aciphex (rabeprazole sodium) for gastrointestinal ills. Features of the drug; Problems with the other PPI; Result of the clinical trial of the drug.

  • Lansoprazole: In the Management of Gastroesophageal Reflux Disease in Children. Scott, L.J. // Pediatric Drugs;2003, Vol. 5 Issue 1, p57 

    â–´ Lansoprazole, a proton pump inhibitor, inactivates the H/K-ATPase pump in parietal cells, thereby suppressing basal and stimulated gastric acid secretion and increasing intragastric pH. â–´ After 8-12 weeks' treatment with lansoprazole, all children (n = 27) with esophagitis at...

  • The anti-secretory and anti-ulcer activities of esomeprazole in comparison with omeprazole in the stomach of rats and rabbits. Salim Bastaki; Irwin Chandranath; Jaipaul Singh // Molecular & Cellular Biochemistry;Feb2008, Vol. 309 Issue 1/2, p167 

    Abstract   Proton pump inhibitors (PPIs) are widely used to treat hyperacid secretion and stomach ulcers. The study investigated the anti-secretory and anti-ulcer effects of esomeprazole, the S-isomer of omeprazole on dimaprit, histamine and dibutyryl adenosine 3, 5 cyclic...

  • Watermelon stomach in a patient with primary Sj�gren's syndrome. Krstic, Miodrag; Alempijevic, Tamara; Andrejevic, Sladjana; Zlatanovic, Maja; Damjanov, Nemanja; Ivanovic, Branislava; Jovanovic, Ivan; Tarabar, Dino; Milosavljevic, Tomica // Vojnosanitetski Pregled: Military Medical & Pharmaceutical Journ;Mar2010, Vol. 67 Issue 3, p256 

    Introduction. Watermelon stomach (WS) or gastric antral vascular ectasia (GAVE) is a rare cause of upper gastrointestinal bleeding described in a variety of autoimmune disorders. Association of watermelon stomach with Sj�gren's syndrome is extremely rare. Case report. We presented a 67-year...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics